Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Severe mania is life-threatening, carries an increased risk of suicide and has a serious impact on patients and their families. Efficient and rapid control of episodes of acute mania is needed. Aims: To evaluate the safety and efficacy of risperidone monotherapy for acute mania. Method: In a 3-week, randomised, double-blind trial, 290 in-patients with bipolar l disorder with current manic or mixed episode and a baseline Young Mania Rating Scale (YMRS) score of 20 or more received flexible doses of risperidone (1–6 mg per day) or placebo. Results: Risperidone was received by 146 patients and placebo by 144. Their mean baselineYMRS score was 37. 2 (s. e. =0. 5). Significantly greater improvements were observed with risperidone than with placebo at weeks l and 2 and at end-point (total YMRS:P<0. 01). Extrapyramidal symptoms were the most frequently reported adverse events in the risperidone group. Conclusions: In patients with severe manic symptoms, risperidone produced significant improvements in YMRS scores as early as week 1 and substantial changes at end-point. Treatment was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Treatment efficacy was determined primarily by the change from baseline to end-point in mean total scores on the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodThe Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424 · cited 5×
“The sample size was based on experience from three recent trials of atypical antipsychotic agents in the treatment of bipolar disorder (Tohen et al, 1999; Sachs et al, 2002; Yatham et al, 2003).”
BackgroundMethodResultSelf-citationYatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248 · cited 5×
“The sample size was based on experience from three recent trials of atypical antipsychotic agents in the treatment of bipolar disorder (Tohen et al, 1999; Sachs et al, 2002; Yatham et al, 2003).”
BackgroundMethodResultSelf-citationSuppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1164 · Cited by 238
Miller, D. S., Yatham, L. N., & Lam, R. W. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1210 · Cited by 103 · cited 1×
“…(Segal et al, 1998; Tohen et al, 1999; Vieta et al, 2004) or in combination with mood stabilisers (Ghaemi et al, 1997; Suppes et al, 1999; Miller et al, 2001; Vieta et al, 2001; Sachs et al, 2002, 2004; Tohen et al, 2002; Yatham et al, 2003), have been shown to be effective and well…”
Background
Cited by
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264
Correll, C. U., Sheridan, E. M., & DelBello, M. P. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00798.x · Cited by 255
Scherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.43 · Cited by 213
“44 Pretrial treatment status Medication-free days, median (range)c 7 (1-600) 3 (1-450) .”
Metadata
- Authors
- Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M., & Kramer, M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2005-09
- Volume
- 187
- Issue
- 3
- Pages
- 229-234
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2135941823
- Cited by
- 188
- References
- 9
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1192/bjp.187.3.229
- The paper
- Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M., & Kramer, M. (2005). Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. British Journal of Psychiatry. https://doi.org/10.1192/bjp.187.3.229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.